胆道恶性肿瘤临床研究进展

doi:10.16139/j.1007-9610.2024.05.15

摘要/Abstract

摘要：

胆道恶性肿瘤（bile tract cancer, BTC）侵袭性强，早期诊断困难。尽管根治性手术是目前BTC的主要治愈性措施，但多数BTC病人就诊时已经处于疾病进展期或晚期。即使接受根治性手术切除，术后肿瘤复发风险也居高不下，5年生存率低。多项关于BTC大规模多中心前瞻性临床研究结果公布，对于优化BTC的治疗方案具有里程碑意义。BILCAP、ASCOT研究肯定辅助化疗在可切除BTC的重要地位。伊立替康作为进展期BTC病人的二线化疗药物也有近期的研究数据证实。TOPAZ-1研究首次宣告一线免疫疗法联合化疗的优效性。在靶向治疗方面，泽尼达妥单抗、T-DXd、奈拉替尼等靶向HER2的药物开发取得突破。 SAGC、SPINE研究显示免疫治疗联合化疗或其他靶向治疗药物生存获益可能更好。基于这些临床研究数据，国内、外相应指南也进行了更新。伴随着现阶段肿瘤分子诊断技术的飞速发展，BTC基因表达信息的深入挖掘，BTC精准医疗研究步入新的时代，期待后续更多的临床研究及真实世界数据分析、更多临床实践应用经验的积累，为BTC病人提供更优的治疗选择。

关键词: 胆道恶性肿瘤, 临床研究, 精准医疗

Abstract:

Bile tract cancer (BTC) is aggressive and difficult to diagnose at an early stage. So far, radical surgery is the main curative measure for BTC, most patients with BTC are already in progressive or advanced stage at the time of diagnosis. Even after radical surgical resection, the risk of tumor recurrence remains high, and the 5-year survival rate is low. The results of several large-scale multicenter prospective clinical trials about BTC were published. All of these are significant for optimizing therapeutic strategies for BTC. BILCAP and ASCOT studies confirm the vital role of adjuvant chemotherapy in resectable BTC. Irinotecan as a second-line chemotherapy agent for patients with advanced BTC has also been confirmed by recent research data. TOPAZ-1 study was the first to demonstrate the superior efficacy of first-line immunotherapy combined with chemotherapy. In terms of targeted therapy, breakthroughs have been made in the development of HER2-targeting drugs such as zanidatamab, T-DXd, and neratinib. SAGC and SPINE studies showed that immunotherapy combined with chemotherapy or other targeted therapeutics may yield better survival benefit. Based on the data from these clinical studies, the corresponding guidelines have been updated both domestically and internationally. Along with the advances of tumor molecular diagnostic technology and the in-depth mining of gene expression information of BTC, BTC precision medical research has entered a new era. We expect more clinical studies and real-world data analysises and more clinical practice application experiences to provide better treatment options for BTC patients.

Key words: Bile tract cancer(BTC), Clinical trial, Precision medicine

中图分类号:

R735.8

熊逸晨, 杨自逸, 桑玉尔, 龚伟. 胆道恶性肿瘤临床研究进展[J]. 外科理论与实践, 2024, 29(05): 455-460.

XIONG Yichen, YANG Ziyi, SANG Yuer, GONG Wei. Proceedings of clinical trials on bile tract cancer[J]. Journal of Surgery Concepts & Practice, 2024, 29(05): 455-460.

参考文献 42

[1]	CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[2]	VOGEL A, BRIDGEWATER J, EDELINE J, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2023, 34(2):127-140.
[3]	SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[4]	李茂岚, 刘颖斌. 胆道恶性肿瘤临床研究进展与展望[J]. 中国实用外科杂志, 2020, 40(2):167-170.
	LI M L, LIU Y B. Progress and prospect of clinical research on biliary tract cancers[J]. Chin J Pract Surg, 2020, 40(2):167-170.
[5]	杨自逸, 刘诗蕾, 蔡晨, 等. 胆囊癌临床诊疗的新进展[J]. 中华外科杂志, 2022, 60(8):784-791.
	YANG Z Y, LIU S L, CAI C, et al. Progress in clinical diagnosis and treatment of gallbladder cancer[J]. Chin J Surg, 2022, 60(8):784-791.
[6]	LAMARCA A, EDELINE J, MCNAMARA M G, et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers[J]. Cancer Treat Rev, 2020,84:101936.
[7]	YOO C, SHIN S H, PARK J O, et al. Current status and future perspectives of perioperative therapy for resectable biliary tract cancer: a multidisciplinary review[J]. Cancers (Basel), 2021, 13(7):1647.
[8]	NARA S, ESAKI M, BAN D, et al. Role of adjuvant and neoadjuvant therapy for resectable biliary tract cancer[J]. Expert Rev Gastroenterol Hepatol, 2021, 15(5):537-545.
[9]	BRIDGEWATER J, FLETCHER P, PALMER D H, et al. Long-term outcomes and exploratory analyses of the randomized phase Ⅲ BILCAP study[J]. J Clin Oncol, 2022, 40(18):2048-2057.
[10]	PRIMROSE J N, FOX R P, PALMER D H, et al. Capecitabine compared with observation in resected bi-liary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study[J]. Lancet Oncol, 2019, 20(5):663-673.
[11]	NAKACHI K, KONISHI M, IKEDA M, et al. A rando-mized phase Ⅲ trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT)[J]. Jpn J Clin Oncol, 2018, 48(4):392-395.
[12]	NAKACHI K, IKEDA M, KONISHI M, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial[J]. Lancet, 2023, 401(10372):195-203. doi: 10.1016/S0140-6736(22)02038-4 pmid: 36681415
[13]	NEUZILLET C. First-line chemotherapy plus immunotherapy in biliary tract cancer[J]. Lancet Gastroenterol Hepatol, 2022, 7(6):496-497.
[14]	LAMARCA A, PALMER D H, WASAN H S, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial[J]. Lancet Oncol, 2021, 22(5):690-701.
[15]	VOGEL A, WENZEL P, FOLPRECHT G, et al. Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio-and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC - AIO-HEP-0116)[J]. Ann Oncol, 2022, 33(suppl 7):S563-S564.
[16]	YOO C, KIM K P, JEONG J H, et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study[J]. Lancet Oncol, 2021, 22(11):1560-1572.
[17]	YOO C, KIM K P, KIM I, et al. Final results from the NIFTY trial, a phase Ⅱb, randomized, open-label study of liposomal Irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC)[J]. Ann Oncol, 2022, 33(suppl_7):S565.
[18]	吴自友, 龚伟. 胆囊癌免疫治疗现状与进展[J]. 中华肝脏外科手术学电子杂志, 2021, 10(1):15-19.
	WU Z Y, GONG W. Recent status and research progress in immunotherapy for gallbladder cancer[J]. Chin J Hepat Surg(Electronic Edition), 2021, 10(1):15-19.
[19]	KASSAB J, SABA L, GEBRAEL G, et al. Update on immunotherapy in the management of gallbladder cancer[J]. Immunotherapy, 2023, 15(1):35-42. doi: 10.2217/imt-2022-0191 pmid: 36617963
[20]	VALLE J, WASAN H, PALMER D H, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14):1273-1281.
[21]	OH D Y, RUTH H A, QIN S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer[J]. NEJM Evid, 2023, 1(8):EVIDoa2200015.
[22]	OH D Y, HE A R, QIN S, et al. A phase A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1[J]. J Clin Oncol, 2022, 40(4_suppl):378.
[23]	VOGEL A, CHEN L T, HE A R, et al. Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced bi-liary tract cancer (BTC)[J]. J Clin Oncol, 2022, 40(16_suppl):4075.
[24]	U.S. FDA. FDA approves durvalumab for locally advanced or metastatic biliary tract cancer (2022)[EB/OL]. [2023-03-07]. www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-locally-advanced-or-metastatic-biliary-tract-cancer.
[25]	VOGEL A, BOECK S, WAIDMANN O, et al. A rando-mized phase Ⅱ trial of durvalumab and tremelimumab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with cholangio- and gallbladder carcinoma (IMMUCHEC)[J]. Ann Oncol, 2022, 33(suppl_7):S563.
[26]	LI J, XU Q, QING W, et al. A phase 2, randomized, open-label, multicenter study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC[J]. J Clin Oncol, 2022, 40(16_suppl):507.
[27]	UENO M, MORIZANE C, IKEDA M, et al. Phase Ⅰ/Ⅱ study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE)[J]. Ann Oncol, 2022, 33(suppl_7):S569-S570.
[28]	VALLE J W, KELLEY R K, NERVI B, et al. Biliary tract cancer[J]. Lancet, 2021, 397(10272):428-444. doi: 10.1016/S0140-6736(21)00153-7 pmid: 33516341
[29]	SONG X, HU Y, LI Y, et al. Overview of current targeted therapy in gallbladder cancer[J]. Signal Transduct Target Ther, 2020, 5(1):230.
[30]	Meric-Bernstam F, Beeram M, Hamilton E, et al. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study[J]. Lancet Oncol, 2022, 23(12):1558-1570.
[31]	JAVLE M, BEKAII-SAAB T, JAIN A, et al. Biliary cancer: utility of next-generation sequencing for clinical management[J]. Cancer, 2016, 122(24):3838-3847. doi: 10.1002/cncr.30254 pmid: 27622582
[32]	HO J, FIOCCO C, SPENCER K. Treating biliary tract cancers: new targets and therapies[J]. Drugs, 2022, 82(17):1629-1647.
[33]	OHBA A, MORIZANE C, UENO M, et al. Multicenter phase Ⅱ trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial[J]. Future Oncol, 2022, 18(19):2351-2360.
[34]	NARAYAN P, DILAWARI A, OSGOOD C, et al. US Food and Drug Administration approval summary: fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2-low unresectable or metastatic breast cancer[J]. J Clin Oncol, 2023, 41(11):2108-2116.
[35]	RIUDAVETS M, SULLIVAN I, ABDAYEM P, et al. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic stra-tegies in NSCLC harbouring HER2 alterations[J]. ESMO Open, 2021, 6(5):100260.
[36]	SAURA C, OLIVEIRA M, FENG Y H, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase Ⅲ NALA trial[J]. J Clin Oncol, 2020, 38(27):3138-3149.
[37]	HARDING J J, PIHA-PAUL S A, SHAH R H, et al. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers[J]. Nat Commun, 2023, 14(1):630. doi: 10.1038/s41467-023-36399-y pmid: 36746967
[38]	WOODS E, LE D, JAKKA BK, et al. Changing landscape of systemic therapy in biliary tract cancer[J]. Cancers(Basel), 2022, 14(9):2137.
[39]	LIN J, CAO Y, YANG X, et al. Mutational spectrum and precision oncology for biliary tract carcinoma[J]. The-ranostics, 2021, 11(10):4585-4598.
[40]	翁海敏, 应杰儿. 胆道恶性肿瘤精准靶向治疗的研究进展[J]. 中华肝胆外科杂志, 2022, 28(12):955-960.
	WENG H M, YING J E. Targeted therapy for biliary tract carcinomas[J]. Chin J Hepatobiliary Surg, 2022, 28(12):955-960.
[41]	YANG Z, WU Z, XIONG Y, et al. Successful conversion surgery for locally advanced gallbladder cancer after gemcitabine and nab-paclitaxel chemotherapy[J]. Front Oncol, 2022,12:977963.
[42]	COFFMAN-D'ANNIBALE K L, GRETEN T F. Top advances of the year: hepatobiliary cancers[J]. Cancer, 2023, 129(8):1149-1155.